✦ LIBER ✦

Low-dose valaciclovir prophylaxis against cytomegalovirus disease in renal transplant recipients

✍ Scribed by SrikanthP. Reddy; Ashok Handa; Liamchin Tan; Andrea Devaney; David Hughes; Phillip Mason; PeterJ. Friend; ChristopherR. Darby

Publisher: Springer
Year: 2003
Tongue: English
Weight: 171 KB
Volume: 16
Category: Article
ISSN: 0934-0874
DOI: 10.1007/s00147-003-0612-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The cost-effectiveness of prophylaxis wi

The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation

✍ Christophe Legendre; Stephen M. Beard; Anne Crochard; Yvon Lebranchu; Claire Pou 📂 Article 📅 2005 🏛 Springer 🌐 French ⚖ 188 KB

Fatal cytomegalovirus disease in a high-

Fatal cytomegalovirus disease in a high-risk renal transplant recipient

✍ Frank Tenney; Abdullah Sakarcan 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 62 KB

Detection of ganciclovir resistance afte

Detection of ganciclovir resistance after valacyclovir-prophylaxis in renal transplant recipients with active cytomegalovirus infection

✍ S. Alain; S. Hantz; C. Scieux; A. Karras; M.C. Mazeron; J.C. Szelag; B.M. Imbert 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 147 KB

## Abstract Whether valaciclovir (VCV) prophylaxis could be responsible for ganciclovir (GCV)‐resistance of __Human cytomegalovirus__ (HCMV) in transplantation has never been documented. A multicentric retrospective pilot study was undertaken to detect GCV‐resistance through mutations within the __

Efficacy and safety of low-dose valganci

Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients

✍ Jeong M. Park; Kathleen D. Lake; Juan D. Arenas; Robert J. Fontana 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 1 views

The efficacy and safety of valganciclovir (VGCV) for cytomegalovirus (CMV) prophylaxis in liver transplant recipients has not been established. We retrospectively compared the efficacy and safety of low-dose oral VGCV (450 mg once daily for 90 days) and standard oral ganciclovir (1 g three times a d

Low correlation of human cytomegalovirus

Low correlation of human cytomegalovirus DNA amplification by polymerase chain reaction with cytomegalovirus disease in organ transplant recipients

✍ Dr. B. Weber; U. Nestler; W. Ernst; H. Rabenau; J. Braner; A. Birkenbach; E.-H. 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 719 KB

## Abstract Seventy‐five organ transplant recipients underwent prolonged virological and serological follow‐up for early detection of human Cytomegalovirus (HCMV) infection after transplantation. HCMV DNA detection by nested polymerase chain reaction (PCR) and HCMV early structural antigen (pp65) d

Mononuclear subsets during cytomegalovir

Mononuclear subsets during cytomegalovirus disease in renal transplant recipients treated with cyclosporine and rabbit antithymocyte globulin

✍ H. J. Metselaar; Ph. H. Rothbarth; G. J. Wenting; L. B. Vaessen; N. Masurel; J. 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 363 KB

The effect of cytomegalovirus (CMV) disease on mononuclear subpopulations of 49 renal transplant recipients treated with cyclosporine and prednisone are reported. Clinical overt CMV infection developed in 8/21 patients treated for rejection with rabbit antithymocyte globulin. They all showed true in